AI Article Synopsis
- The study aimed to assess the effectiveness of F-PSMA-1007 PET/CT imaging in detecting prostate cancer in patients with varying prostate-specific antigen (PSA) levels.
- A systematic review of 15 studies involving 1,022 patients was performed, showing a detection rate (DR) of 94% for primary staging and 86% for biochemical recurrence (BCR) cases.
- Results indicated that higher PSA levels correlated with better detection rates, highlighting F-PSMA-1007 PET/CT as a valuable tool for diagnosing both primary and recurrent prostate cancer.
Article Abstract
Background: We performed a systematic review and meta-analysis to evaluate the detection rate (DR) of fluoro-prostate-specific membrane antigen (F-PSMA-1007) PET/CT in patients with different serum prostate-specific antigen (PSA) levels in the setting of primary staging of prostate cancer (PCa) or biochemically recurring PCa.
Methods: A comprehensive electronic literature search of the PubMed, Embase, and Cochrane Library databases was conducted in accordance with the PRISMA statement. This study was registered in the PROSPERO database (registration number: CRD42022331595). We calculated the DR of F-PSMA-1007 PET/CT in PCa.
Results: The final analysis included 15 studies that described 1,022 patients and 2,034 lesions with F-PSMA-1007 PET/CT in PCa. The DR of F-PSMA-1007 PET/CT in patients with PCa in primary staging ranged from 90% to 100%, with a pooled estimate of 94% (95% CI: 92%-96%). The DR of F-PSMA-1007 PET/CT in patients with PCa in BCR ranged from 47% to 100%, with a pooled estimate of 86% (95% CI: 76%-95%). The DRs of PSA levels >2.0, 1.1-2.0, 0.51-1.0, and ≤0.5 ng/ml detected by F-PSMA-1007 PET/CT in a patient-based analysis were 97% (95% CI: 93%-99%), 95% (95% CI: 88%-99%), 79% (95% CI: 68%-88%), and 68% (95% CI: 58%-78%), respectively.
Conclusion: This meta-analysis concluded that F-PSMA-1007 PET/CT had a high application value for prostate cancer, including primary tumors and biochemical recurrence. The DR of F-PSMA-1007 PET/CT was slightly higher in primary prostate tumors than in biochemical recurrence.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022331595.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353183 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.911146 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Semi-standardized evaluation of extraprostatic extension and seminal vesicle invasion with [F]PSMA-1007 PET/CT: a comparison to MRI using histopathology as reference.
EJNMMI Rep
January 2025
Department of Translational Medicine, Lund University, Lund, Sweden.
Background: Positron emission tomography/computed tomography (PET/CT) with prostate specific membrane antigen ligands (PSMA) is established for use in primary staging of prostate cancer to screen for metastases. It has also shown promise in local tumor staging, including detection of extraprostatic extension (EPE) and seminal vesicle invasion (SVI). Previous studies have shown high heterogeneity in methods and results.
View Article and Find Full Text PDFThree-dimensional spatial localization and volume estimation of prostate tumors using F-PSMA-1007 PET/CT versus multiparametric MRI.
Eur J Nucl Med Mol Imaging
December 2024
Division of Urology, Department of Surgery, University of Alberta, Edmonton, Canada.
Purpose: Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed tomography (F-PSMA-1007 PET/CT) has been shown to be superior to multiparametric magnetic resonance imaging (MRI) for the locoregional staging of intermediate-risk and high-risk prostate tumors. This study aims to evaluate whether it is also superior in estimating tumor parameters, such as three-dimensional spatial localization and volume.
Methods: 134 participants underwent F-PSMA-1007 PET/CT and MRI prior to radical prostatectomy as part of the validating paired-cohort Next Generation Trial (NCT05141760).
The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.
Br J Cancer
December 2024
PET/CT Center, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China.
Background: The diagnostic utility of prostate biopsy is limited for prostate cancer (PCa) in the prostate-specific antigen (PSA) grey zone. This study aims to evaluate the diagnostic performance of multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for PSA grey zone PCa and clinically significant PCa (csPCa).
Methods: A total of 82 patients with PSA levels ranging from 4 to 10 ng/mL who underwent F-PSMA-1007 PET/CT, mpMRI, and prostate biopsy were prospectively enrolled.
Radical prostatectomy without prostate biopsy based on a noninvasive diagnostic strategy: a prospective single-center study.
Prostate Cancer Prostatic Dis
December 2024
Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Background: Prostate biopsy is the most common approach for diagnosing prostate cancer (PCa); however, it has inherent limitations, such as the invasive procedure, postoperative complications, and false negative results. We aimed to provide a noninvasive diagnostic strategy for patients with highly suspected PCa and to evaluate the feasibility of performing biopsy-spared radical prostatectomy.
Methods: This prospective study included a total of 57 patients between November 10, 2022, and December 1, 2023.
The quantitative impact of prostate-specific membrane antigen (PSMA) PET/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implications.
BJR Open
January 2024
Division of Radiotherapy and Imaging, Institute of Cancer Research, London, SW3 6JB, United Kingdom.
Objectives: To quantify the stage-shift with prostate-specific membrane antigen (PSMA) PET/CT imaging in metastatic prostate cancer and explore treatment implications.
Methods: Single-centre, retrospective analysis of patients with newly diagnosed [F]PSMA-1007 or [Ga]Ga-PSMA-11 PET/CT-detected metastatic prostate cancer who had baseline bone scintigraphy between January 2015 and May 2021. Patients were subclassified into oligometastatic and polymetastatic disease utilizing the STAMPEDE2 trial (ISRCTN66357938/NCT06320067) definition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!